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Is 99m Tc-methylene diphosphonate bone scintigraphy a sensitive 
method for detecting bone lesions in multiple myeloma? 
  
Abstract 
Background: Bone lesion in multiple myeloma (MM) is most commonly presented as a 
lytic lesion in this disease. Determination of extent of bone lesions in MM is necessary to 
follow-up the patients. Whole body bone scan with 99m, Tc-methylene diphosphonate 
(MDP) has a lower sensitivity than other modalities. 
Methods: From the patients with MM admitted to Ayatollah Rouhani Hospital of Babol-
Iran from 2009 to 2015, who had undergone whole body bone scan during diagnostic 
process, were entered into the study. Findings of bone scan were compared with MRI. 
Results: Of the 19 patients, sixteen (84.2%) of them had positive finding in bone scan, 
fifteen (78.9%) had MRI of the spine. While of the thirteen patients who had positive finding in 
MRI, seven (53.8%) had more positive finding in thorcolumbosacral MRI than in bone scan. 
Conclusions: 99m-Tc MDP bone scan is a sensitive but insufficient method for detecting 
bone lesions in MM. 
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Multiple myeloma (MM) is a malignant disease of plasma cell due to its clonal 
proliferation. Bone lesion is a diagnostic criteria for MM and may present as lytic lesion, 
expansile mass lesion and/or osteopenia. Determining the extent of bone lesions in MM is 
necessary to follow-up the patients. Plain radiography, magnetic resonance imaging 
(MRI), positron-emission tomography/computed tomography (PET/CT) and Tc99m 
sestamibi (MIBI) scan have reasonable sensitivity for this purpose. Malignant plasma cells 
produce osteoclast activating factors (OAF), includingIL-1,IL-3 pathway,lymphotoxin, 
VEGF, tumor necrosis factor, macrophage inhibitory factor (MIP)-1 alpha/ᵦ, and receptor 
activator of NF-kappa B (RANK) ligand. Osteoblast activity is suppressed in MM with 
dickhoff-1 (DKK-1) produced by myeloma cells (1, 2). As a result, for detecting  
osteolytic bone lesions, plain radiography is better than isotopic bone scintigraphy (bone 
scan) (2), but it seems scintigraphy has a reasonable sensitivity. In this article, we reviewed 
the findings of 99m-Tc MDP bone scintigraphy in our MM patients.  
 
Methods 
The patients with MM admitted to Ayatollah Rouhani Hospital of Babol from 2009 to 
2015 were evaluated; those who had undergone whole body bone scan during diagnostic 
process, entered into the study. Diagnosis of MM was done based on the last criteria of 
International Multiple Myeloma Working Group:1-equal or more than 10% plasma cells in 
bone marrow examination, 2- presence of monoclonal gammopathy in serum or urine and 
3-an end organ damage (hemoglobin>2gr/dL below the lower limit of normal value or less 
than 10gr/dL, creatinine clearance <40 ml/min or creatinine> 2mg/dl, one or more lytic 
bone lesions and hypercalcemia) (3). 
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Bone lesions in thorcolumbosacral MRI reported with 
different radiologists were compared with bone scan 
findings. Whole body bone scan was performed with TC99 
methylene diphosphonate (MDP) in different centers. The 
patients ‘data were analyzed with SPSS Version 22.  
 
 
Results 
Sixty-seven patients were evaluated from 2009 to 2015 
and 19 patients entered the study.  Thirteen (68.4%) of the 
patients were males and six (31.6%) were females. Their 
mean age was 59.16±12.75 years. 18 (94.7%) patients had 
bone pain at presentation. Table 1 demonstrates some data of 
the patients. 
Table 1: Some charactristics of studied population 
 
Mean(±SD) Maximum Minimum Variable 
59.16±12 81 39 Age(year) 
9±2.05 12.4 3.6 Hemoglobin(gr/dL) 
205±80 335000 51000 Platelet(/μL) 
7376±3642 15300 3500 White blood cell(/μL) 
83±31 130 12 ESR(1 hour) 
 
Of the six women, one had hemoglobin level of 10.8gr/dl 
and another one with hemoglobin level of 12.4gr/dl at 
presentation and four patients had anemia. Of the 11 men, all 
had anemia, as a result, 88.3% of the patients had anemia at 
presentation. Other abnormal laboratory findings are 
demonstrated in table 2.   
 
Table 2: Frequency of some abnormal laboratory finding 
of the patients 
N (%) Variable 
3(15.8) Leucopenia(<4000/µL) 
18(94.7) Anemia 
5(21.1) Thrombocytopenia(<150000/µL) 
2(10.5) Hypercalcemia(>1mg/dL higher than the upper 
limit of normal) 
6(31.6) Renal failure(creatinine>1.2mg/dL) 
17(89.5) Increased ESR 
8(42.1) Hypoalbuminemia(<3.5gr/dL) 
 
Of the 19 patients, sixteen (84.2%) had positive finding 
in bone scan. Fifteen (78.9%) patients had MRI of the spine. 
Two patients had negative finding not only in the bone scan 
but also in the MRI. Of the thirteen patients who had positive 
finding in MRI, seven (53.8%) patients had more positive 
finding in thorcolumbosacral MRI than in bone scan; 
certainly heterogeneity of bone marrow was seen in these 
cases in MRI. Of the 19 patients, seventeen (89.5%) had 
skull x-ray. Only ten (52.6%) had one or more punched- out 
lesions.  
 
 
Discussion 
The extent of bone lesions in MM can be determined 
with several methods. Plain x-ray, whole-body x-ray 
(WBXR) survey, is a conventional method and includes 
chest x-ray, skull x-ray, humeri, femoral bones, pelvic, 
cervical, thorasic and lumbosacral spine. But x-ray becomes 
positive when 50-70% of bone is lost, and has low sensitivity 
to detect early lytic lesions. Whole body MRI is another and 
more sensitive method (1, 2).  
Recently (18) fluorine-fluorodeoxyglucose ((18) F-FDG) 
positron-emission tomography/computed tomography 
(PET/CT) has been confirmed as a sensitive (80-90%) and 
specific method (90-100%) (4-6). Durie-Salmon plus 
classification MRI and FDG-PET/CT scan, are both 
recommended7. In Durie-Salmon plus classification, MRI 
and FDG-PET/CT scan are both recommended (7). MRI is 
more sensitive for detecting bone marrow infiltration with 
malignant plasma cells than PET/CT scan (4). Whole-body 
low dose CT is a new method, and may replace x-ray 
(8).Bone scintigraphy is not recommended for the 
assessment of bone lesions in MM via medicine textbooks 
but interesting results exist in the literature (9).  
Weng et al. in a systematic review of scintigraphy 
(Tc99m Sestamibi), MRI, FDG-PET and PET/CT for 
diagnosis of bone lesions in MM find equal sensitivity for 
the detection of osteolytic lesions between these procedures, 
with pooled sensitivity and specificity of 0.98 and 0.90, 0.88 
and 0.68, 0.99 and 0.69, respectively. Furthermore, for bone 
scan, they were 0.66 and 0.83 (10). 
Whole body Tc99m sestamibi was compared to Tc99m 
MDP by Alexandrakis et al. Sestamibi scan detects bone 
lesions in 78.5% of the 28 patients with MM and Tc99m 
MDP detects 53.5% (11). These values were 100% and 75%, 
respectively from 20 patients in the study of Alper E et al. 
(12). In another study, whole body sestamibi scan was very 
sensitive for evaluating the extent of bone lesions in MM 
(13). When amyloidosis complicates MM, Tc99m MDP 
scintigraphy can detect amyloid deposition besides bone 
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lesions (14, 15). In one study, sensitivity and accuracy for 
the detection of bone metastasis was 85.7% and 70.1%, for 
bone scan and 97.1% and 92.3% for FDG-PET/CT (16). In 
another study, sensitivity and specificity for detection of 
bone metastasis of head and neck cancer were 88% and 98% 
for bone scan and 100% for PET/CT (17). 
In our study, TC99m MDP bone scan was positive in 
84.2% of the cases that is more sensitive than previous 
studies. Although in 53.8% of the cases, MRI is better for the 
detection of the extent of thoracolumbosacral spine lesions 
but bone scan is more feasible for the detection of bone 
lesions in the ribs and the extremity bones. PET/CT scan is 
available only in Tehran and is very expensive. With 
practical standpoint, we cannot perform neither whole body 
MRI nor PET/CT scan and Tc99m sestamibi scan is costly 
and not available extensively, as a result, we can perform 
whole body Tc99m MDP bone scan besides  skull x-ray, 
chest x-ray and cervical thoracolumbosacral MRI for the 
detection and follow-up of bone lesions. 
The important limitations of this study were the different 
centers for bone scan and different radiologists for MRI 
reporting. We suggest a prospective study in which bone 
scan and MRI be done for all patients in a single center. In 
conclusion, we showed that whole body Tc99m MDP bone 
scan has reasonable sensitivity for the detection of bone 
lesions in MM and can be used as a modality for this purpose 
in addition to other feasible methods.  
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